Cargando…

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)

Background: Pasireotide has proven efficacy in acromegaly and CD, although pasireotide-associated hyperglycemia occurs in some patients (pts). We present results from a Phase IV, randomized, open-label study investigating optimal management of pasireotide-associated hyperglycemia uncontrolled by met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samson, Susan, Gu, Feng, Feldt-Rasmussen, Ulla, Zhang, Shaoling, Yu, Yerong, Witek, Przemyslaw, Pedroncelli, Alberto, Nauwelaerts, Heidi, Jabbour, Nadine, Paul, Michaela, Bolanowski, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550842/ http://dx.doi.org/10.1210/js.2019-MON-LB079

Ejemplares similares

THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide
por: Samson, Susan Leanne, et al.
Publicado: (2023)

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

MON-LB52 Evaluation of Arterial Stiffness in Acromegaly Patients
por: alagüney, sevil, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-LB078 Desmopressin Stimulated Salivary Cortisol as a Suplementary Tool in the Diagnosis of Cushing's Syndrome
por: Firme, Ricardo
Publicado: (2019)

MON-457 One in Five Patients Develop Multiple Hormone Deficiencies Following Radiotherapy for Acromegaly or Cushing's Disease
por: Shen, Angeline, et al.
Publicado: (2019)

MON-LB58 The Use of 11C Methionine PET CT In Localization of ACTH Dependent Cushing’s Disease
por: ElEbrashy, Shady Ibrahim, et al.
Publicado: (2020)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

SUN-LB074 Racial Distribution, Presentation and Outcome in Acromegaly and Cushing's Disease: A Tertiary Referral Center Study in 220 Patients
por: Goswami, Neevedita, et al.
Publicado: (2019)

MON-LB46 Thyrotropinoma and Pregnancy
por: Namboodiri, Divya, et al.
Publicado: (2020)

MON-LB51 Stimulation for Bilateral Inferior Petrosal Sinus Sampling May Be Unnecessary for Diagnosis of ACTH Dependent Cushing Syndrome
por: Builes-barrera, Carlos Alfonso, et al.
Publicado: (2020)

SAT-LB079 Clinical Heterogeneity of Acquired Idiopathic ACTH Deficiency: A New Classification Based on the Clinical Characteristics and Autoantibodies
por: FUJITA, YASUNORI, et al.
Publicado: (2019)

MON-302 The Prevalence of Acromegaly in the Sleep Apnoea Clinic
por: Lynch, Julie Marie, et al.
Publicado: (2020)

MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI
por: Martel, Luciana, et al.
Publicado: (2019)

MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission
por: Martel, Luciana, et al.
Publicado: (2019)

MON-LB48 The Genomic Landscape of Sporadic Thyrotrophinomas
por: shen, Angeline, et al.
Publicado: (2020)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
por: Samson, Susan L., et al.
Publicado: (2021)

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial
por: Gadelha, Mônica, et al.
Publicado: (2023)

SAT-LB48 Novel Genetic Variant of Carney Complex With Acromegaly
por: Cristiano, Elizabeth, et al.
Publicado: (2020)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

SAT-LB46 Depression as an Atypical Presentation of Cushing’s Disease
por: Pahwa, Dhivya, et al.
Publicado: (2020)

MON-310 Factors Associated with Remission After Surgery for Acromegaly
por: Cunha, Clara, et al.
Publicado: (2020)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

MON-298 IGF-1 in the Early Post-operative Assessment of Acromegaly
por: Donegan, Diane, et al.
Publicado: (2020)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

MON-LB081 Pituitary Adenomas: A Pan-genomic Classification
por: NEOU, Mario, et al.
Publicado: (2019)

SAT-LB078 Acromegaly Disease Activity According to ACRODAT® in Spain: ACROVAL Study
por: Marazuela, Monica, et al.
Publicado: (2019)

MON-317 Prognostic Factors and Mortality According to the Structural and Functional Classification of Acromegaly
por: Haro, Andrea Rocha, et al.
Publicado: (2020)

MON-268 Factors Associated With QoL Impairment In Patients With Acromegaly In The Elderly
por: Yamamoto, Naoki, et al.
Publicado: (2020)

MON-412 Subclinical Cushing's Disease and the Importance of Broad Differential Diagnoses
por: Walker, Michelle, et al.
Publicado: (2019)

MON-461 Drug Repurposing to Explore Novel Treatment for Cushing Disease
por: Zhang, Dongyun, et al.
Publicado: (2019)

MON-403 Osteoporosis: A Frequently Neglected Consequence of Cushing's Disease
por: Pedro, Jorge, et al.
Publicado: (2019)

LBODP079 A Case of Silent Invasive Corticotroph Adenoma
por: Bendaram, Snigdha Reddy, et al.
Publicado: (2022)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rr7638u77kk36q32nvi4qdkpqv